Update – Novelties in neoadjuvant therapy of breast cancer

Neoadjuvant chemotherapy (NACT) has become a mainstay of treatment for patients with triple-negative breast cancer (TNBC), and human epidermal growth factor 2 (HER2) positive BC. In these patients pathological complete response (pCR) is correlated with long term outcome and allows to adapt adjuvant treatment. Some patients with hormone receptor (HR) positive HER2-negative BC also require NACT, mainly because of locoregionally advanced disease or aggressive biology.